


Claims

1. A serine protease inhibitor of formula (I):



5

wherein:

R_2 is a 5 or 6 membered aromatic carbon ring optionally interrupted by a nitrogen, oxygen or sulphur ring atom,
10 optionally being substituted in the 3 and/or 4 position (in relation to the point of attachment of $X-X$) by halo, nitro, thiol, haloalkoxy, hydrazido, alkylhydrazido, amino, cyano, haloalkyl, alkylthio, alkenyl, alkynyl, acylamino, tri or difluoromethoxy, carboxy, acyloxy, $MeSO_2^-$ or R_1 , or the
15 substituents at the 3 or 4 positions taken together form a fused ring which is a 5 or 6 membered carbocyclic or heterocyclic ring optionally substituted by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R_{1j} , and optionally substituted in the position
20 alpha to the $X-X$ group (i.e. 6 position for a six membered aromatic ring etc) by amino, hydroxy, halo, alkyl, carboxy, alkoxy carbonyl, cyano, amido, aminoalkyl, alkoxy or alkylthio with the proviso that R_2 cannot be aminoisoquinolyl;
each X independently is a C, N, O or S atom or a CO,
25 CR_{1a} , $C(R_{1a})_2$ or NR_{1a} group, at least one X being C, CO, CR_{1a} or $C(R_{1a})_2$;
each R_{1a} independently represents hydrogen or hydroxyl, alkoxy, alkyl, aminoalkyl, hydroxyalkyl, alkoxyalkyl, alkoxy carbonyl, alkylaminocarbonyl, alkoxy carbonyl amino,
30 acyloxymethoxycarbonyl or alkylamino optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl;
 R_1 is as defined for R_{1a} , provided that R_1 is not

contd.

a¹

unsubstituted aminoalkyl;

Y (the α -atom) is a nitrogen atom or a CR_{1b} group;


Cy is a saturated or unsaturated, mono or poly cyclic, homo or heterocyclic group, optionally substituted by groups

5 R_{3a} or R_{3i}X_i;each R_{3a} independently is R_{1c}, amino, halo, cyano, nitro, thiol, alkylthio, alkylsulphonyl, alkylsulphenyl, triazolyl, imidazolyl, tetrazolyl, hydrazido, alkylimidazolyl, thiazolyl, alkylthiazolyl, alkyloxazolyl, oxazolyl, alkylsulphonamido,10 alkylaminosulphonyl, aminosulphonyl, haloalkoxy, haloalkyl, a group of the formula -C(X³)N(R¹¹)R¹² (wherein X³ is O or S; and R¹¹ and R¹² are independently selected from hydrogen, methyl or ethyl or together with the nitrogen atom to which they are attached form a pyrrolidin-1-yl, piperidin-1-yl or 15 morpholino group), or -OCH₂O- which is bonded to two adjacent ring atoms in Cy;X_i is a bond, O, NH or CH₂;R_{3i} is phenyl, pyridyl or pyrimidinyl optionally substituted by R_{3a}; and20 R_{1b}, R_{1c} and R_{1j} are as defined for R_{1a};

L is an organic linker group containing 1 to 5 backbone atoms selected from C, N, O and S, or a branched alkyl or cyclic group; and

L_p(D)_n is of the formula:

25



in which:

r is 1 or 2;

X_a is CH and X_b is N;

30 s, t and u are each 0 or 1;


La and Lb are each independently selected from a single bond, C=O, O and NR_{1e}, in which R_{1e} is hydrogen or (1-

contd.
a¹

(6C)alkyl;

G is (1-6C)alkanediyl; and

R₁₀ is (1-6C)alkyl; (3-6C)cycloalkyl [which is unsubstituted or substituted by (1-6C)alkyl]; indanyl; 5 pyridyl; tetrahydropyranyl; tetrahydrothiopyranyl; phenyl {which is unsubstituted or substituted by one or two R₃ groups [wherein R₃ is hydrogen, hydroxyl, alkoxy, alkyl (optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl), hydroxyalkyl (optionally substituted by hydroxy, 10 alkylamino, alkoxy, oxo, aryl or cycloalkyl), alkoxyalkyl, alkoxycarbonyl, alkylaminocarbonyl, alkoxycarbonylamino, acyloxymethoxycarbonyl, aminoalkyl (optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl), alkylamino (optionally substituted by hydroxy, alkylamino, 15 alkoxy, oxo, aryl or cycloalkyl), amino, halo, cyano, nitro, thiol, alkylthio, alkylsulphonyl, alkylsulphenyl, triazolyl, imidazolyl, tetrazolyl, hydrazido, alkyl imidazolyl, thiazolyl, alkyl thiazolyl, alkyl oxazolyl, oxazolyl, alkylsulphonamido, alkylaminosulphonyl, aminosulphonyl, 20 haloalkoxy, or haloalkyl]}, pyrrolinyl; or a group of formula:



in which v is 1, 2 or 3; one of X_c and X_d is N and the other is CH or N (provided that when v is 1, X_c and X_d are not both N);

25 and R₁₁ is hydrogen, (1-6C)alkyl or when X_d is CH, hydroxy(1-6C)alkyl; provided that when t is 0, the sum of s and u is 1; when X_b is N, L_a is a bond or C=O; when X_c is N, L_b is a bond or C=O; when X_b and X_c are both N, t is 1; and when (L_a)_s-
(G)_t-(L_b)_u represents an alkyl group and X_b and X_c both 30 represent N, the alkyl group contains at least two chain carbon atoms;


or R₁₀ is hydrogen and s, t and u are each 0;

contd.
a¹

or the compound of formula (I) that is 4-{[4-methoxybenzoyl-D,L-(2-trifluoromethylthiophenyl)-glycinyl]aminomethyl}-1-isopropylpiperidine;
or a physiologically-tolerable salt thereof.

5

2. A serine protease inhibitor of formula (I):



10 wherein:

R_2 is a 5 or 6 membered aromatic carbon ring optionally interrupted by a nitrogen, oxygen or sulphur ring atom, optionally being substituted in the 3 and/or 4 position (in relation to the point of attachment of X-X) by halo, nitro, 15 thiol, haloalkoxy, hydrazido, alkylhydrazido, amino, cyano, haloalkyl, alkylthio, alkenyl, alkynyl, acylamino, tri or difluoromethoxy, carboxy, acyloxy, MeSO_2^- or R_1 , or the substituents at the 3 or 4 positions taken together form a fused ring which is a 5 or 6 membered carbocyclic or 20 heterocyclic ring optionally substituted by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R_{1j} , and optionally substituted in the position alpha to the X-X group (i.e. 6 position for a six membered aromatic ring etc) by amino, hydroxy, halo, alkyl, carboxy, 25 alkoxy carbonyl, cyano, amido, aminoalkyl, alkoxy or alkylthio with the proviso that R_2 cannot be aminoisoquinolyl; each X independently is a C, N, O or S atom or a CO, CR_{1a} , $\text{C}(\text{R}_{1a})_2$ or NR_{1a} group, at least one X being C, CO, CR_{1a} or $\text{C}(\text{R}_{1a})_2$;


30 each R_{1a} independently represents hydrogen or hydroxyl, alkoxy, alkyl, aminoalkyl, hydroxyalkyl, alkoxyalkyl, alkoxy carbonyl, alkylaminocarbonyl, alkoxy carbonyl amino.

*contd.**a¹*

acyloxy methoxycarbonyl or alkylamino optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl;

R₁ is as defined for R_{1a}, provided that R₁ is not unsubstituted aminoalkyl;

5 Y (the α -atom) is a nitrogen atom or a CR_{1b} group;
 Cy is a saturated or unsaturated, mono or poly cyclic, homo or heterocyclic group optionally substituted by groups R_{3a} or phenyl optionally substituted by R_{3a};
 each R_{3a} independently is R_{1c}, amino, halo, cyano, nitro,
 10 thiol, alkylthio, alkylsulphonyl, alkylsulphenyl, triazolyl, imidazolyl, tetrazolyl, hydrazido, alkyl imidazolyl, thiazolyl, alkyl thiazolyl, alkyl oxazolyl, oxazolyl, alkylsulphonamido, alkylaminosulphonyl, aminosulphonyl, haloalkoxy or haloalkyl; and
 15 R_{1b}, R_{1c} and R_{1j} are as defined for R_{1a};
 L is an organic linker group containing 1 to 5 backbone atoms selected from C, N, O and S, or a branched alkyl or cyclic group; and
 L_p(D)_n is of the formula:



in which:

r is 1 or 2;

X_a is CH and X_b is N;

s, t and u are each 0 or 1;


25 L_a and L_b are each independently selected from a single bond, C=O, O and NR_{1e}, in which R_{1e} is hydrogen or (1-6C)alkyl;

G is (1-6C) alkanediyl; and

contd.

a 1

~~R₁₀ is (1-6C)alkyl; (3-6C)cycloalkyl [which is unsubstituted or substituted by (1-6C)alkyl]; indanyl; pyridyl; tetrahydropyranyl; tetrahydrothiopyranyl; phenyl [which is unsubstituted or substituted by one or two R₃ groups 5 [wherein R₃ is hydrogen, hydroxyl, alkoxy, alkyl (optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl), hydroxyalkyl (optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl), alkoxyalkyl, alkoxycarbonyl, alkylaminocarbonyl, alkoxycarbonylamino, 10 acyloxymethoxycarbonyl, aminoalkyl (optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl), alkylamino (optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl), amino, halo, cyano, nitro, thiol, alkylthio, alkylsulphonyl, alkylsulphenyl, triazolyl, 15 imidazolyl, tetrazolyl, hydrazido, alkyl imidazolyl, thiazolyl, alkyl thiazolyl, alkyl oxazolyl, oxazolyl, alkylsulphonamido, alkylaminosulphonyl, aminosulphonyl, haloalkoxy or haloalkyl], pyrrolinyl; or a group of formula:~~



~~20 in which v is 1, 2 or 3; one of X_c and X_d is N and the other is CH or N, provided that when v is 1, X_c and X_d are not both N; and R₁₁ is hydrogen, (1-6C)alkyl or when X_d is CH, hydroxy(1-6C)alkyl; provided that when t is 0, the sum of s and u is 1; when X_b is N, L_a is a bond or C=O; when X_c is N, 25 L_b is a bond or C=O; when X_b and X_c are both N, t is 1; and when (L_a)_s-(G)_t-(L_b)_u represents an alkyl group and X_b and X_c both represent N, the alkyl group contains at least two chain carbon atoms,~~

~~or a physiologically-tolerable salt thereof.~~

30 3. A serine protease inhibitor according to claim 1 or claim


contd.

a¹

2, wherein R³ is selected from hydrogen, hydroxyl, methoxy, ethoxy, methyl, ethyl, propyl, 2-propyl, butyl, 2-butyl, t-butyl, pentyl, 2-pentyl, 3-pentyl, isopropylaminomethyl, dimethylamino-methyl, diethylaminomethyl, dimethylaminoethyl, 5 acetyl, hydroxymethyl, hydroxyethyl, carboxy, carboxy(1-5C)alkyl, methoxymethyl, methoxycarbonyl, ethoxycarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, aminomethyl, aminocarbonyl, aminocarbonyl(1-5C)alkyl, methylamino, dimethylamino, ethylamino, formylamino, acetylamino, amino, 10 fluoro, chloro, cyano, nitro, thiol, methylthio, methylsulphonyl, ethylsulphonyl, isopropylsulphonyl, methylsulphenyl, 1,2,4-triazol-2-yl, 1,2,4-triazol-4-yl, 1,2,3-triazol-4-yl, 1,3-imidazol-1-yl, 1,3-imidazol-4-yl, tetrazol-1-yl, tetrazol-5-yl, methylsulphonamido, ethylsulphonamido, 15 propylsulphonamido, methylaminosulphonyl, ethylaminosulphonyl, propylaminosulphonyl, aminosulphonyl, trifluoromethoxy, trifluoromethyl and trichloromethyl.

4. A compound according to any of claims 1 to 3 wherein r is 20 2.

5. A compound according to claim 1 wherein L_p(D)_n is of the formula:



25 wherein:


q is 1 or 2;

R_s is hydrogen, -(CH₂)_c-R_c, -CHR_eR_f, or -CH₂-CHR_eR_f [c is 0, 1 or 2; wherein R_c is pyridyl or phenyl (which phenyl may bear a fluoro, chloro, methyl, CONH₂, SO₂NH₂,

methylaminosulphonyl, dimethylaminosulphonyl,
 methylsulphonylamino, methoxy or methylsulphonyl substituent)
 and R_e and R_f are independently hydrogen or C_{1-3} alkyl; or
 CHR_eR_f is (3-6C)cycloalkyl (which may bear a methyl, ethyl or
 5 hydroxymethyl substituent at the 3- or 4-position, provided
 the substituent is not bonded to the CH group which is bonded
 to L), tetrahydropyranyl, tetrahydrothiopyranyl, pyrrolidinyl
 (which may bear a 1-methyl substituent), piperidinyl (which
 may bear a 1-methyl substituent) (provided that the
 10 tetrahydropyranyl, tetrahydrothiopyranyl, pyrrolidinyl and
 piperidinyl rings are not linked to the piperidin-1,4-diyl
 group through a ring nitrogen atom or a ring carbon atom
 adjacent to a ring oxygen, sulfur or nitrogen atom) or indan-
 2-yl].
 15

6. A compound according to any one of claims 1 to 5 wherein
 L is $CONH$, CH_2NHCO , $CONHCH_2$, $CONHCH_2CH_2$ or $CON(Me)CH_2$.

7. A serine protease inhibitor according to claim 2 wherein
 $-L-Lp(D)_n$ is of the formula:



wherein

q is 1 or 2;

s is 0 or 1; and


R_s is $-(CH_2)_c-R_c$, $-CHR_eR_f$, or $-CH_2-CHR_eR_f$ [wherein c is 1
 25 or 2; R_c is pyridyl or phenyl (which phenyl may bear a fluoro,
 chloro, methyl, $CONH_2$, SO_2NH_2 , methylaminosulphonyl,
 dimethylaminosulphonyl, methylsulphonylamino, methoxy or
 methylsulphonyl substituent) and R_e and R_f are independently

S. ch
β1


hydrogen or C₁-3-alkyl; or CH₂R_f is cyclopentyl (which may bear a methyl, ethyl or hydroxymethyl substituent at the 3- or 4-position), cyclohexyl (which may bear a methyl, ethyl or hydroxymethyl substituent at the 3- or 4-position),
 5 tetrahydropyran-4-yl, tetrahydrothiopyran-4-yl, pyrrolidin-3-yl (which may bear a 1-methyl substituent), piperidin-4-yl (which may bear a 1-methyl substituent), or indan-2-yl].

Amen. *Ar³* 8. A compound according to any of claims 5 to 7 wherein q is

10 2. 9. A compound according to claim 1 or claim 2 wherein L_p(D)_n is selected from one of the following formulae:



contd.
a³



wherein m represents 0 or 1.

5 10. A compound according to any of claims 5 to 7 wherein R₅
is selected from: hydrogen, methyl, ethyl, prop-2-yl, but-2-
yl, pent-3-yl, hept-4-yl, cyclopentyl, cyclohexyl,
cyclohexylmethyl, 1-methylpiperidin-4-yl, tetrahydropyran-4-
yl, tetrahydrothiopyran-4-yl, phenyl, benzyl, pyrid-2-yl,
10 pyrid-3-yl, pyrid-4-yl, pyrid-3-ylmethyl, pyrid-4-ylmethyl and
indan-2-yl.


11. A compound according to any one of claims 1 to 10 wherein
R₂ is phenyl, thien-2-yl, naphthyl, indol-2-yl, indol-6-yl,
15 benzo[b]furan-5-yl, benzo[b]thiophen-2-yl or benzimidazol-2-yl
(each of which is optionally substituted as defined in claim
1).

12. A compound according to any one of claims 1 to 11 wherein
20 optional substituents for R₂ are selected from:
fluoro, chloro, bromo, iodo, nitro, thiol, difluoromethoxy,
trifluoromethoxy, hydrazido, methylhydrazido, amino, cyano,
trifluoromethyl, methylthio, vinyl, ethynyl, acetylamino,
carboxy, acetoxy, hydroxy, methyl, ethyl, amido (CONH₂),
25 aminomethyl, methoxy and ethoxy.

13. A compound according to any one of claims 1 to 12 wherein
R₂ is selected from one of the formula (A') to (H')

- 179 -

contd.
 a^3



wherein X_4 is O or S, R_{13} is selected from hydrogen, fluoro, chloro or methyl and R_{14} is selected from hydrogen, methyl, ethyl, fluoro, chloro, and methoxy and R_{15} is selected from hydrogen, methyl, fluoro, chloro and amino.

14. A compound according to claims 1 to 13, wherein R₂ is 4-methoxyphenyl, 3-amino-4-chlorophenyl, indol-2-yl, 5-chloroindol-2-yl, indol-6-yl, 3-chloroindol-6-yl or 3-methylindol-6-yl.

15. A compound according to any one of claims 1 to 14 wherein
-X-X- is -CONH-.

*contd.**a 3*

16. A compound according to any one of claims 1 to 15 wherein
Y is CH.

5 17. A compound according to any one of claims 1 to 16 wherein
Cy is an optionally R_{3a} substituted: phenyl, pyridyl, thienyl,
thiazolyl, naphthyl, piperidinyl, furanyl, pyrrolyl,
isoxazolyl, isothiazolyl, pyrazolyl, oxazolyl, imidazolyl,
1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, pyrimidinyl,

10 pridazinyl, quinolyl, isoquinolyl, benzofuryl, benzothienyl or
cycloalkyl group, or a phenyl group substituted by R_{3i}X_i in
which X_i is a bond, O, NH or CH₂ and R_{3i} is phenyl, pyridyl or
pyrimidinyl optionally substituted by R_{3a}.

15 18. A compound according to any one of claims 1 to 17
wherein Cy is an optionally R_{3a} substituted: phenyl, pyridyl,
thienyl, thiazolyl, naphthyl, piperidinyl or cycloalkyl group

19. A compound according to any one of claims 1 to 18 wherein
20 R_{3a} is selected from hydrogen, hydroxyl, alkoxy, alkyl
(optionally substituted by hydroxy, alkylamino, alkoxy, oxo,
aryl or cycloalkyl), aminoalkyl (optionally substituted by
hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl),
hydroxyalkyl (optionally substituted by hydroxy, alkylamino,
25 alkoxy, oxo, aryl or cycloalkyl), alkoxyalkyl, alkoxycarbonyl,
alkylaminocarbonyl, alkoxycarbonylamino, alkylamino
(optionally substituted by hydroxy, alkylamino, alkoxy, oxo,
aryl or cycloalkyl), for amino, halo, cyano, nitro, thiol,
alkylthio, alkylsulphonyl, alkylsulphenyl, alkylsulphonamido,
30 alkylaminosulphonyl, aminosulphonyl, haloalkoxy, haloalkyl, a
group of the formula -C(X³)N(R¹¹)R¹² (wherein X³ is O or S;
and R¹¹ and R¹² are independently selected from hydrogen,
methyl or ethyl or together with the nitrogen atom to which
they are attached form a pyrrolidin-1-yl, piperidin-1-yl or

~~morpholino group) and -OCH₂O- which is bonded to two adjacent ring atoms in Cy.~~

20. A compound according to any one of claims 1 to 19 wherein
5 R_{3a} is selected from hydrogen, hydroxyl, alkoxy, alkyl
(optionally substituted by hydroxy, alkylamino, alkoxy, oxo,
aryl or cycloalkyl), hydroxyalkyl (optionally substituted by
hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl),
alkoxyalkyl, alkoxy carbonyl, alkylaminocarbonyl,
10 alkoxy carbonylamino, alkylamino (optionally substituted by
hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl),
aminoalkyl (substituted by hydroxy, alkylamino, alkoxy, oxo,
aryl or cycloalkyl), halo, cyano, nitro, thiol, alkylthio,
alkylsulphonyl, alkylsulphenyl, alkylsulphonamido,
15 alkylaminosulphonyl, aminosulphonyl, haloalkoxy and haloalkyl.

Amen. *An*
21. A compound according to any one of claims 1 to 19 wherein
R_{3a} is selected from hydrogen, hydroxyl, methoxy, ethoxy,
methyl, ethyl, methylaminomethyl, dimethylaminomethyl,
20 hydroxymethyl, carboxy, methoxymethyl, methoxycarbonyl,
ethoxycarbonyl, methylaminocarbonyl, dimethylamino-carbonyl,
aminomethyl, CONH₂, CH₂CONH₂, acetyl amino,
methoxycarbonylamino, ethoxycarbonylamino, t-
butoxycarbonylamino, amino, fluoro, chloro, bromo, cyano,
25 nitro, thiol, methylthio, methylsulphonyl, ethylsulphonyl,
methylsulphenyl, methylsulphonylamido, ethylsulphonylamido,
methylaminosulphonyl, ethylaminosulphonyl, aminosulphonyl,
trifluoromethoxy, trifluoromethyl, pyrrolidin-1-ylcarbonyl,
piperidin-1-ylcarbonyl, morpholin-1-ylcarbonyl and -OCH₂O-
30 (which is bonded to two adjacent ring atoms in Cy).


22. A compound according to any one of claims 1 to 19 wherein
R_{3a} is selected from hydrogen, hydroxyl, methoxy, ethoxy,
methyl, ethyl, methylaminomethyl, dimethylaminomethyl

contd
a4

hydroxymethyl, carboxy, methoxymethyl, methoxycarbonyl,
ethoxycarbonyl, methylaminocarbonyl, dimethylamino-carbonyl,
aminomethyl, CONH₂, CH₂CONH₂, acetylarnino,
methoxycarbonylamino, ethoxycarbonylamino, t-
5 butoxycarbonylamino, amino, fluoro, chloro, cyano, nitro,
thiol, methylthio, methylsulphonyl, ethylsulphonyl,
methylsulphenyl, methylsulphonylamido, ethylsulphonylamido,
methylaminosulphonyl, ethylaminosulphonyl, aminosulphonyl,
trifluoromethoxy and trifluoromethyl.

10

23. A compound according to any one of claims 1 to 22 wherein
Cy is selected from:



15

wherein:

X' is selected from O, S and NMe;

X'' is selected from O and S;

contd.
a4

~~X''' is selected from O, S, NH and NMe;~~
~~Y' is selected from hydrogen, amino and methyl;~~
~~R_o is selected from hydrogen, methyl, fluoro, chloro,~~
~~trifluoromethyl, methoxy, methylthio, methylsulphanyl and~~
5 ~~methylsulphonyl;~~

~~R_m is selected from hydrogen, methyl, fluoro, chloro,~~
~~trifluoromethyl, methoxy, methylthio, methylsulphanyl,~~
~~methylsulphonyl, carboxy, methoxycarbonyl and a group of the~~
~~formula -C(X³)N(R¹¹)R¹² (wherein X³ is O or S and R¹¹ and R¹²~~
10 ~~are independently selected from hydrogen, methyl or ethyl or~~
~~together with the nitrogen atom to which they are attached~~
~~form a pyrrolidin-1-yl, piperidin-1-yl or morpholino group);~~
~~R_p is selected from hydrogen and fluoro; or~~
~~R_o and R_m or R_m and R_p form an -OCH₂O- group; or~~
15 ~~R_o and R_m together with the ring to which they are attached~~
~~form a 5 or 6 membered aryl or heteroaryl ring (wherein the~~
~~heteroaryl ring contains 1 or 2 heteroatoms selected from~~
~~nitrogen, oxygen and sulfur);~~
one of R_{o1} and R_{o2} is hydrogen and the other is R_o;

20

24. A compound according to any one of claims 1 to 19 wherein Cy is selected from phenyl, 2-chlorophenyl, 2-methoxyphenyl, 4-carbamoylphenyl, pyrid-2-yl, pyrid-3-yl, thien-2-yl, thien-3-yl, furan-2-yl, furan-3-yl, imidazol-2-yl, thiazol-2-yl, 25 thiazol-4-yl, thiazol-5-yl, naphthyl, isoquinolin-5-yl, isoquinolin-8-yl, quinolin-4-yl, quinolin-5-yl, and quinolin-8-yl.

25. A compound as claimed in any one of Claims 1 to 24, in
30 which the alpha atom in Y is carbon and has the conformation
that would result from construction from a D- α -aminoacid
NH₂-CR_{1b}(Cy)-COOH where the NH₂ represents part of X-X

26. A pharmaceutical composition, which comprises a compound

contd. *a⁴* ~~as claimed in any one of claims 1 to 25 together with at least one pharmaceutically acceptable carrier or excipient.~~

27. A compound as claimed in any one of claims 1 to 25 for use in therapy. *a*

28. Use of a compound as claimed in any one of claims 1 to 25 for the manufacture of a medicament for the treatment of a thrombotic disorder. *a*

a⁵ 10 29. A method of treatment of a human or non-human animal body to combat a thrombotic disorder, which comprises administering to said body an effective amount of a compound as claimed in claim 1. *a*

15 30. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 25 for use to combat a thrombotic disorder. *a*

20 31. A compound of formula I as claimed in claim 1 and named in any of the Examples herein, or a physiologically-tolerable salt thereof. *a*

add
B1